Related Experiment Videos
Acyclovir inhibition of Epstein-Barr virus replication
Summary
Acyclovir triphosphate selectively inhibits Epstein-Barr virus DNA polymerase more than host polymerases. This antiviral activity reduces viral genome numbers in infected cells, suggesting a competitive inhibition mechanism.
Area of Science:
- Virology
- Molecular Biology
- Pharmacology
Background:
- Epstein-Barr virus (EBV) is a human herpesvirus associated with various cancers.
- Antiviral therapies targeting viral DNA polymerases are crucial for managing EBV infections.
- Acyclovir is a nucleoside analog used to treat herpesvirus infections.
Purpose of the Study:
- To investigate the mechanism of acyclovir triphosphate inhibition on EBV-associated DNA polymerase.
- To compare the inhibitory effects of acyclovir triphosphate on viral and host DNA polymerases.
- To assess the impact of acyclovir on EBV replication in cell culture.
Main Methods:
- Enzyme kinetics assays were performed to determine the inhibitory activity of acyclovir triphosphate against EBV DNA polymerase and host alpha/beta DNA polymerases.
- The effect of deoxyguanosine triphosphate on inhibition was evaluated.
- EBV-infected cell line P3HRF-1 was treated with acyclovir to measure viral genome numbers and capsid antigen expression.
Main Results:
- Acyclovir triphosphate exhibited significantly higher affinity for EBV DNA polymerase (100-fold) compared to host alpha-polymerase.
- Inhibition was dependent on template-primer base composition and could be overcome by deoxyguanosine triphosphate.
- Prolonged acyclovir exposure in P3HRF-1 cells led to reduced viral genome numbers and capsid antigen, which were reversible upon drug removal.
Conclusions:
- Acyclovir triphosphate competitively inhibits EBV-associated DNA polymerase.
- The selective inhibition of viral DNA polymerase by acyclovir contributes to its antiviral efficacy against EBV.
- Acyclovir demonstrates potential as a therapeutic agent for EBV-related diseases.